<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Our objective was to study acquired Activated Protein C (APC) resistance in patients with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) using a thrombin generation based assay </plain></SENT>
<SENT sid="1" pm="."><plain>We compared patients with and without <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> (<z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, SLE) </plain></SENT>
<SENT sid="2" pm="."><plain>A parameter summarizing APC inhibition of thrombin generation with increasing APC concentrations (IC(50)-APC) was increased in <z:hpo ids='HP_0000001'>all</z:hpo> patient groups compared to controls: median values were 15.3 (interquartile range, IQR, 9.7 to 34.0) in patients with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (APS), 27.3 (IQR 23.5 to 43.5) in patients with SLE without APS, 64.1 (IQR 25.9 to 65.0) in patients with SLE/APS compared to 10.4 [IQR 8.5 to 15.8] in controls, respectively p = 0.003, p = 0.0001 and p = 0.0001 </plain></SENT>
<SENT sid="3" pm="."><plain>In conclusion, patients with SLE and primary APS displayed a <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> characterized by APC resistance </plain></SENT>
</text></document>